Everything below concerns growth hormone secretagogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility class | Soluble in water and aqueous buffers | Solubility can depend on pH and salt form |
| Typical storage temperature | −20 °C or lower, desiccated | Protect from light and moisture |
| Typical analytical method | RP-HPLC with UV detection; LC-MS | Identity and purity assessment |
| Common salt form | Acetate salt | Frequently used in research supply |
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
== Resin types == While the main type of resins used are based on epoxy resin, vinyl ester-based prepregs are also available. Since vinyl ester resins must be pre-accelerated with amine accelerator or cobalt, their processing time at room temperature is shorter than with epoxy-based prepregs. Catalysts (also called hardeners) include peroxides such as methyl ethyl ketone peroxide (MEKP), acetyl acetone peroxide (AAP) or cyclohexanone peroxide (CHP). Vinyl ester resin is used under high impact stress.
==== Patron–client networks ==== Patron–client networks are defined by fluid interactions. They produce crime groups that operate as smaller units within the overall network, and as such tend towards valuing significant others, familiarity of social and economic environments, or tradition. These networks are usually composed of:
=== Data queries === Where data entered does not pass validation rules then a data query may be issued to the investigative site where the clinical trial is conducted to request clarification of the entry. Data queries must not be leading (i.e. they must not suggest the correction that should be made). For electronic CRFs only the site staff with appropriate access may modify data entries. For paper CRFs, the clinical data manager applies the data query response to the database and a copy of the data query is retained at the investigative site. When an item or variable has an error or a query raised against it, it is said to have a “discrepancy” or “query”. All EDC systems have a discrepancy management tool or also refer to “edit check” or “validation check” that is programmed using any known programming language (e.g. SAS, PL/SQL, C#, SQL, Python, etc). So what is a ‘query’? A query is an error generated when a validation check detects a problem with the data. Validation checks are run automatically whenever a page is saved “submitted” and can identify problems with a single variable, between two or more variables on the same eCRF page, or between variables on different pages. A variable can have multiple validation checks associated with it. Errors can be resolved in several ways:
The goal of protein design is to find a protein sequence that will fold to a target structure. A protein design algorithm must, thus, search all the conformations of each sequence, with respect to the target fold, and rank sequences according to the lowest-energy conformation of each one, as determined by the protein design energy function. Thus, a typical input to the protein design algorithm is the target fold, the sequence space, the structural flexibility, and the energy function, while the output is one or more sequences that are predicted to fold stably to the target structure. The number of candidate protein sequences, however, grows exponentially with the number of protein residues; for example, there are 20100 protein sequences of length 100. Furthermore, even if amino acid side-chain conformations are limited to a few rotamers (see Structural flexibility), this results in an exponential number of conformations for each sequence. Thus, in our 100 residue protein, and assuming that each amino acid has exactly 10 rotamers, a search algorithm that searches this space will have to search over 200100 protein conformations. The most common energy functions can be decomposed into pairwise terms between rotamers and amino acid types, which casts the problem as a combinatorial one, and powerful optimization algorithms can be used to solve it. In those cases, the total energy of each conformation belonging to each sequence can be formulated as a sum of individual and pairwise terms between residue positions.
Sources: en.wikipedia.org
Reports indicated that oil prices rose above 100 USD per barrel, while jet fuel prices increased significantly, in some cases more than doubling compared to the previous month. European markets were identified as particularly vulnerable, with concerns raised over potential fuel shortages within weeks if supply conditions did not stabilise. Industry groups and analysts warned that continued disruption could lead to operational challenges at European airports, including potential flight cancellations and capacity constraints. The International Air Transport Association (IATA) noted that even in the event of a reopening of the Strait of Hormuz, recovery in jet fuel supply could take months due to persistent constraints in refining capacity and logistics across the region. In response to the rising energy prices, the European Central Bank and the Bank of England left interest rates unchanged.
Not all earthworms become two worms when cut in half. Only a limited number of earthworm species are capable of anterior regeneration. Applying urine to jellyfish stings does not relieve pain and may make the pain worse. The best immediate treatment for jellyfish stings is to rinse them in salt water. For some kinds of jellyfish stings, adding vinegar helps.
=== Marketing controversy === In 2001, Eli Lilly's chairman, president and CEO, Sidney Taurel, told shareholders: "No medicine better symbolizes our mission than Xigris," calling it "one of our industry's genuine breakthroughs." Xigris was designed to fight sepsis, a condition that kills more than 200,000 Americans annually. It was the only approved drug for sepsis, and it costs $8,000 to treat a single patient. Lilly hoped it would be a blockbuster, with sales of at least a billion dollars a year. But, after five years on the market, sales were only $200 million. Eli Lilly used the Belsito & Company PR firm in a marketing campaign to promote Xigris. A report accused the company of initiating false reports of a shortage of the drug to boost sales. Belsito and Company spread the word that the drug was being "rationed" and physicians were being 'systematically forced' to decide who would live and who would die. As part of this effort, Lilly provided a group of physicians and bioethicists with a $1.8 million grant to form the Values, Ethics, and Rationing in Critical Care (VERICC) Task Force, purportedly to address ethical issues raised by rationing in the intensive care unit. Finally, the Surviving Sepsis Campaign was established, in theory to raise awareness of severe sepsis and generate momentum toward the development of treatment guidelines. This marketing campaign was especially troublesome because Xigris has been linked to increased risk of serious bleeding in patients who used it as well as other concerns.
=== Allegations of patent infringement on mRNA technology (2022) === In August 2022, Moderna announced that it will sue Pfizer and its partner BioNTech for infringing its patent on the mRNA technology. In May 2024, the European Patent Office upheld the validity of Moderna's EP949 patent, one of the two patents asserted against Pfizer and BioNTech.
== Diagnosis == Diagnosis of infectious disease sometimes involves identifying an infectious agent either directly or indirectly. In practice most minor infectious diseases such as warts, cutaneous abscesses, respiratory system infections and diarrheal diseases are diagnosed by their clinical presentation and treated without knowledge of the specific causative agent. Conclusions about the cause of the disease are based upon the likelihood that a patient came in contact with a particular agent, the presence of a microbe in a community, and other epidemiological considerations. Given sufficient effort, all known infectious agents can be specifically identified. Diagnosis of infectious disease is nearly always initiated by medical history and physical examination. More detailed identification techniques involve the culture of infectious agents isolated from a patient. Culture allows identification of infectious organisms by examining their microscopic features, by detecting the presence of substances produced by pathogens, and by directly identifying an organism by its genotype. Many infectious organisms are identified without culture and microscopy. This is especially true for viruses, which cannot grow in culture. For some suspected pathogens, doctors may conduct tests that examine a patient's blood or other body fluids for antigens or antibodies that indicate presence of a specific pathogen that the doctor suspects.
Sources: en.wikipedia.org
He also accused the Russian military of laying mines targeting his personnel as they retreated. The governor of Russia's Bryansk Oblast claimed that Ukrainian forces shelled a village along the international border, destroying a house. Two people were reportedly killed and two others injured when Ukrainian forces shelled a road in Maslova Pristan, Belgorod Oblast, while the Freedom of Russia Legion claimed responsibility for an attack on the village of Novaya Tavolzhanka and claimed that Russian government forces had killed two civilians after mistaking their vehicle for that of the legion. Long-range drones hit two towns in Smolensk Oblast, while an explosion was reported in a forest in Kaluga Oblast. Officials claimed that buildings were damaged in Bryansk and Kursk by Ukrainian shelling and a nighttime drone attack. Russian Deputy Prime Minister Viktoria Abramchenko said Russia sowed winter crops for the year's harvest in the territories it annexed during the invasion, providing state support worth 3 billion rubles ($37.1 million) to farmers in the occupied regions and harvesting grain, beans and rapeseed on 1.3 million hectares. The Chairman of the US Joint Chiefs of Staff General Mark Milley announced that Ukrainian soldiers had begun training in the use of M1 Abrams tanks pledged to Ukraine by the West. The United States approached Japan for supplies of TNT to be used in 155 mm caliber shells for Ukraine. According to Reuters, the Japanese government allowed the US government to purchase industrial TNT as it is not a military product.
=== MAGNET designation === In 2008, Southern Ohio Medical Center became the first hospital in the tri-state region (Ohio, Kentucky, West Virginia) to earn Magnet Recognition from the American Nurses Credentialing Center. The Magnet Recognition Program recognizes healthcare organizations for quality patient care, nursing excellence and innovations in professional nursing practice. In 2011, less than 7% of hospitals in the United States were able to achieve Magnet Recognition. SOMC earned Magnet re-designation in 2013.
== Further reading == Barrett, Duncan, Calvi, Nuala (2012). The Sugar Girls. Collins. ISBN 978-0-00-744847-0. Chisholm H, ed. (1911). "Sugar" . Encyclopædia Britannica (11th ed.). Cambridge University Press. Frankopan, Peter, The Silk Roads: A New History of the World, 2016, Bloomsbury, ISBN 9781408839997 Saulo, Aurora A. (March 2005). "Sugars and Sweeteners in Foods" (PDF). College of Tropical Agriculture and Human Resources. Strong, Roy (2002), Feast: A History of Grand Eating, Jonathan Cape, ISBN 0224061380
The viscosity of honey is affected greatly by both temperature and water content. The higher the water percentage, the more easily honey flows. Above its melting point, however, water has little effect on viscosity. Aside from water content, the composition of most types of honey also has little effect on viscosity. At 25 °C (77 °F), honey with 14% water content generally has a viscosity around 400 poise, while a honey containing 20% water has a viscosity around 20 poise. Viscosity increases very slowly with moderate cooling; a honey containing 16% water, at 70 °C (158 °F), has a viscosity around 2 poise, while at 30 °C (86 °F), the viscosity is around 70 poise. With further cooling, the increase in viscosity is more rapid, reaching 600 poise at around 14 °C (57 °F). However, while honey is viscous, it has low surface tension of 50–60 mJ/m2, making its wettability similar to water, glycerin, or most other liquids. The high viscosity and wettability of honey cause stickiness, which is a time-dependent process in supercooled liquids between the glass-transition temperature (Tg) and the crystalline-melting temperature. Most types of honey are Newtonian liquids, but a few types have non-Newtonian viscous properties. Honeys from heather or mānuka display thixotropic properties. These types of honey enter a gel-like state when motionless, but liquefy when stirred.
Thiophanate-methyl is an organic compound with the formula C6H4(NHC(S)NH(CO)OCH3)2. The compound is a colorless or white solid, although commercial samples are generally tan-colored. It is prepared from o-phenylenediamine. It is a widely used fungicide used on tree, vine, and root crops. In Europe it is applied to tomato, wine grapes, beans, wheat, and aubergine. Methods for its analysis have received considerable attention. It is commonly used to treat botrytis bunch rot and gray mold caused by Botrytis cinerea strawberry in California. Thiophanate-methyl acts as a fungicide via its primary metabolite carbendazim.
Sources: en.wikipedia.org
Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.
Lyophilized powder is usually kept frozen, desiccated, and protected from light. Reconstituted solutions are often divided into aliquots and stored at very low temperature to limit freeze-thaw cycles. Specific conditions should follow the supplier's certificate of analysis and the assay requirements.
Much of the evidence comes from animal models and cell-based assays rather than large human trials. Small sample sizes, short follow-up, and differences in dosing or route make comparisons difficult. Questions about long-term effects and human relevance remain open.
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.